Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CETP | P11597 | 4/20 | 0.47 |
| ▸ | PPARG | P37231 | 2/20 | 0.42 |
| ▸ | PPARA | Q07869 | 2/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.42 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.40 |
| ▸ | CARM1 | Q86X55 | 2/20 | 0.40 |
| ▸ | PRMT6 | Q96LA8 | 2/20 | 0.40 |
| ▸ | DAO | P14920 | 1/20 | 0.39 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23095166 | 0.90 | CETP (0.48) | CETPCHRM2CHRM1CHRM3TAAR1 | |
| SCHEMBL22057298 | 0.85 | CETP (0.46) | CETPPPARGPPARACHRM2CHRM1 | |
| SCHEMBL18896317 | 0.84 | CETP (0.48) | CETPCHRM2CHRM1CHRM3TAAR1 | |
| SCHEMBL23085168 | 0.81 | CETP (0.50) | CETPPPARGPPARATAAR1 | |
| SCHEMBL7610809 | 0.80 | PPARA (0.62) | CETPPPARGPPARACHRM2CHRM1 | |
| SCHEMBL22957820 | 0.80 | CARM1 (0.44) | CETPPPARGPPARACARM1PRMT6 | |
| SCHEMBL2662597 | 0.79 | CETP (0.51) | CETPCHRM2CHRM1CHRM3TAAR1 | |
| SCHEMBL22096418 | 0.79 | PPARA (0.64) | PPARGPPARACHRM2CHRM1CHRM3 | |
| SCHEMBL7946272 | 0.78 | PPARA (0.56) | CETPPPARGPPARACHRM2CHRM1 | |
| SCHEMBL14478257 | 0.78 | TAAR1 (0.65) | CETPCHRM2CHRM1CHRM3TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11548883-B2 | Compounds as autotaxin inhibitors and pharmaceutical compositions comprising the same | LEGOCHEM BIOSCIENCES, INC. (KR) | 2023-01-10 | — | — | US | disclosed |
| US-20200407350-A1 | NOVEL COMPOUNDS AS AUTOTAXIN INHIBITORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | LIGACHEM BIOSCIENCES INC. (KR) | 2020-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11548883-B2 | Compounds as autotaxin inhibitors and pharmaceutical compositions comprising the same | ENPP2, PLA2G10, LPCAT1 | CETP 60/4885PPARG 3808/4885PPARA 2370/4885 |
| US-20200407350-A1 | NOVEL COMPOUNDS AS AUTOTAXIN INHIBITORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | ENPP2, LPCAT1, PLA2G10 | CETP 58/4885PPARG 3971/4885PPARA 2408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.